Aljiffry Murad M, Dahal Bayan M, Baeisa Razana S, Alzahrani Amal A, Alshahrany Taif A, Hijji Sumiah B, Alsahafi Majid A, Saleem Abdulaziz M, Alghamdi Waleed S, Mosli Mahmoud H
From the Department of Surgery (Aljiffry, Dahal, Baeisa, Alzahrani, Saleem, Alshahrany), from the Department of Medicine (Hijji, Alsahafi, Alghamdi, Mosli), from the Faculty of Medicine (Aljiffry, Daha, Baeisa, Alzahrani, Alshahrany, Hijji, Alsahafi, Saleem, Alghamdi, Mosli), King Abdulaziz University, from the Inflammatory Bowel Disease Research Group (Alsahafi, Mosli), and from the Gastrointestinal Oncology Unit (Saleem, Alghamdi), King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia.
Saudi Med J. 2025 Jan;46(1):52-58. doi: 10.15537/smj.2025.46.1.20240758.
To evaluate the features and frequency of hepatobiliary diseases in individuals with Inflammatory bowel disease (IBD).
This retrospective study included all IBD patients at King Abdulaziz University Hospital in Jeddah, Saudi Arabia. The primary focus was on the prevalence of hepatobiliary diseases, such as primary sclerosing cholangitis (PSC), non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis (AIH), and others. The secondary focus was identifying predictors of these hepatobiliary manifestations in IBD patients. Associations were analyzed using simple and multiple logistic regression analyses.
Among a total of 885 patients with IBD patients, 4.3% presented with hepatobiliary manifestations. Of these cases, 31.6% were linked to Crohn's disease (CD). While 65.8% were associated with ulcerative colitis (UC). Primary sclerosing cholangitis (PSC) was most prevalent, especially in females. PSC was linked to specific IBD sites 39.3% of UC patients have the left-sided disease and 10.7% of patients with ileocolonic CD had PSC. The absence of comorbidities was associated with lower odds of developing PSC, while UC diagnosis, adalimumab use, and infliximab use were associated with higher odds of developing PSC.
A small percentage of IBD patients experience hepatobiliary complications, with PSC being the most prevalent. The study emphasizes the importance of closely monitoring IBD patients, especially those undergoing anti-TNF therapy.
评估炎症性肠病（IBD）患者肝胆疾病的特征及发生率。
这项回顾性研究纳入了沙特阿拉伯吉达阿卜杜勒阿齐兹国王大学医院的所有IBD患者。主要关注肝胆疾病的患病率，如原发性硬化性胆管炎（PSC）、非酒精性脂肪性肝病（NAFLD）、自身免疫性肝炎（AIH）等。次要关注点是确定IBD患者这些肝胆表现的预测因素。使用简单和多元逻辑回归分析来分析相关性。
在总共885例IBD患者中，4.3%出现了肝胆表现。在这些病例中，31.6%与克罗恩病（CD）有关。而65.8%与溃疡性结肠炎（UC）有关。原发性硬化性胆管炎（PSC）最为常见，尤其是在女性中。PSC与特定的IBD部位有关，39.3%的UC患者患有左侧疾病，10.7%的回结肠型CD患者患有PSC。无合并症与发生PSC的几率较低有关，而UC诊断、使用阿达木单抗和英夫利昔单抗与发生PSC的几率较高有关。
一小部分IBD患者会出现肝胆并发症，其中PSC最为常见。该研究强调了密切监测IBD患者的重要性，尤其是那些接受抗TNF治疗的患者。
